Menu

CALL: (661) 257-8400

Menu

Laser Vein Removal

Permanently destroy dark spider veins with CoolGlide® Laser Vein Removal for flawless, ageless beauty.

CALL NOW!

Great for treating veins On the:

LEGS

FEET

Chest

face

Spider veins are named after the “web” of blue or red veins that often begin to appear near the surface of our skin.

This hereditary phenomenon is caused by an increase of pressure in our veins as we age. Most commonly found behind the knee, unsightly spider veins can make both men and women feel tremendously self-conscious. The occurrence of dark spider veins often keeps people from enjoying social occasions and wearing the outfits they once loved. Traditionally, those brave enough, have turned to sclerotherapy, where unwanted veins are injected with a solution that irritates the blood vessel and causes it to collapse.

CoolGlide® Laser Vein Removal provides a modern and effective alternative to treating bothersome spider veins!

Our CoolGlide® 1064 YAG laser permanently destroys spider and reticular veins on any part of the body and is safer and less painful than sclerotherapy injections. This non-invasive treatment uses light energy to cause the vein to shrink and ultimately disappear. Typically, leg veins can be treated in just three sessions and facial veins in just one. Cherry Hemangiomas (small red dots) that appear on many areas of the body are also treatable with CoolGlide® – no compression garments or prolonged downtime needed!

Before

After

Before

After

EXPERT TIP:

Treatments should be spaced six to eight weeks apart. Many people go on vacation in the spring and summer where they want to wear skirts and shorts, but are too embarrassed by spider veins to show their legs. Ideally, these patients should start their laser vein treatments in the winter. That way, there will be plenty of time to complete all the sessions needed in order for them to enjoy their results by spring or early summer.

Dr. Ingber, M.D.

Dermacure is an aesthetic medical office owned and operated by Craig Ingber, MD a board certified Facial Plastic Surgeon.

Dr. Ingber is a clinical instructor of surgery at UCLA Medical School and performs all injections upon request. He is a top 1% injector of Botox and Juvederm in the nation and is the #1 physician injector in Santa Clarita Valley.

LEARN MORE ABOUT DR. INGBER

Permanently banish unsightly spider and reticular veins for ageless, flawless beauty.

Read More

KYBELLA® (deoxycholic acid) injection 10 mg/mL Important Information

INDICATION
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS 
KYBELLA® is contraindicated in the presence of infection at the injection sites.

WARNINGS AND PRECAUTIONS
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.

Injection Site Alopecia
Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Injection Site Ulceration and Necrosis
Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.

ADVERSE REACTIONS
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see KYBELLA® full Prescribing Information.

*Individual results may vary.

Permanently banish unsightly spider and reticular veins for ageless, flawless beauty.

Read More

KYBELLA® (deoxycholic acid) injection 10 mg/mL Important Information

INDICATION
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS 
KYBELLA® is contraindicated in the presence of infection at the injection sites.

WARNINGS AND PRECAUTIONS
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.

Injection Site Alopecia
Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Injection Site Ulceration and Necrosis
Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.

ADVERSE REACTIONS
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see KYBELLA® full Prescribing Information.

*Individual results may vary.

I'm Interested!

Please contact me with more information on this procedure.

©2018 DermaCure Valencia | Web Design by Small Dog Creative